Dizal (Jiangsu) Pharmaceutical Statistics

Total Valuation

Dizal (Jiangsu) Pharmaceutical has a market cap or net worth of CNY 20.20 billion. The enterprise value is 20.31 billion.

Market Cap	20.20B
Enterprise Value	20.31B

Important Dates

The next estimated earnings date is Wednesday, February 26, 2025.

Earnings Date	Feb 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Dizal (Jiangsu) Pharmaceutical has 415.65 million shares outstanding. The number of shares has increased by 1.03% in one year.

Current Share Class	n/a
Shares Outstanding	415.65M
Shares Change (YoY)	+1.03%
Shares Change (QoQ)	-1.25%
Owned by Insiders (%)	3.20%
Owned by Institutions (%)	20.32%
Float	121.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	51.29
PB Ratio	47.15
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-24.25
EV / Sales	52.11
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-23.56

Financial Position

The company has a current ratio of 1.72, with a Debt / Equity ratio of 2.07.

Current Ratio	1.72
Quick Ratio	1.57
Debt / Equity	2.07
Debt / EBITDA	n/a
Debt / FCF	-1.05
Interest Coverage	-51.59

Financial Efficiency

Return on equity (ROE) is -122.20% and return on invested capital (ROIC) is -44.28%.

Return on Equity (ROE)	-122.20%
Return on Assets (ROA)	-36.02%
Return on Capital (ROIC)	-44.28%
Revenue Per Employee	670,632
Profits Per Employee	-1.44M
Employee Count	581
Asset Turnover	0.24
Inventory Turnover	0.50

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.70% in the last 52 weeks. The beta is 0.27, so Dizal (Jiangsu) Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	+4.70%
50-Day Moving Average	43.92
200-Day Moving Average	40.48
Relative Strength Index (RSI)	58.86
Average Volume (20 Days)	3,521,154

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Dizal (Jiangsu) Pharmaceutical had revenue of CNY 389.64 million and -837.22 million in losses. Loss per share was -2.04.

Revenue	389.64M
Gross Profit	375.99M
Operating Income	-955.46M
Pretax Income	-928.34M
Net Income	-837.22M
EBITDA	-916.28M
EBIT	-955.46M
Loss Per Share	-2.04

Full Income Statement

Balance Sheet

The company has 808.30 million in cash and 903.95 million in debt, giving a net cash position of -95.65 million or -0.23 per share.

Cash & Cash Equivalents	808.30M
Total Debt	903.95M
Net Cash	-95.65M
Net Cash Per Share	-0.23
Equity (Book Value)	437.25M
Book Value Per Share	1.03
Working Capital	410.02M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -762.06 million and capital expenditures -99.92 million, giving a free cash flow of -861.98 million.

Operating Cash Flow	-762.06M
Capital Expenditures	-99.92M
Free Cash Flow	-861.98M
FCF Per Share	-2.07

Full Cash Flow Statement

Margins

Gross margin is 96.50%, with operating and profit margins of -245.22% and -214.87%.

Gross Margin	96.50%
Operating Margin	-245.22%
Pretax Margin	-238.26%
Profit Margin	-214.87%
EBITDA Margin	-235.16%
EBIT Margin	-245.22%
FCF Margin	-221.23%

Dividends & Yields

Dizal (Jiangsu) Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.03%
Shareholder Yield	-1.03%
Earnings Yield	-4.19%
FCF Yield	-4.27%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Dizal (Jiangsu) Pharmaceutical has an Altman Z-Score of 4.31.

Altman Z-Score	4.31
Piotroski F-Score	n/a